



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Reslizumab

Cat. No.:	HY-P9949
CAS No.:	241473-69-8
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with $K_D$ values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively <sup>[1][2]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	IL-5 91.1 pM (IC <sub>50</sub> )									
<b>In Vitro</b>	<p>Reslizumab (Sch 55700) (0-10 nM, 48 h) inhibits IL-5-dependent cell proliferation, with an IC<sub>50</sub> value of approximately 91.1pM [1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human erythroleukemic TF-1 cell line</td> </tr> <tr> <td>Concentration:</td> <td>0-10 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Showed antiproliferative activity with an IC<sub>50</sub> of 91.1 pM.</td> </tr> </table>		Cell Line:	Human erythroleukemic TF-1 cell line	Concentration:	0-10 nM	Incubation Time:	48 h	Result:	Showed antiproliferative activity with an IC <sub>50</sub> of 91.1 pM.
Cell Line:	Human erythroleukemic TF-1 cell line									
Concentration:	0-10 nM									
Incubation Time:	48 h									
Result:	Showed antiproliferative activity with an IC <sub>50</sub> of 91.1 pM.									
<b>In Vivo</b>	<p>Reslizumab (Sch 55700) (0-10 mg/kg; i.p. or i.m.) inhibits pulmonary eosinophilia in a dose-dependent manner in allergic mice<sup>[3]</sup>.</p> <p>Reslizumab (0.03-30 mg/kg; i.p.) inhibits both the pulmonary eosinophilia and airway hyperresponsiveness, and at 30 mg/kg, i.p. inhibits allergic, but not histamine-induced bronchoconstriction in allergic guinea pigs<sup>[3]</sup>.</p> <p>Reslizumab (0.1-1 mg/kg; i.p.) blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs<sup>[3]</sup>.</p> <p>Reslizumab (0.3 mg/kg; i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months in allergic cynomolgus monkeys<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male B6D2F1/J mice weighing 20–25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 μg of ovalbumin (OVA) adsorbed to 2 mg of aluminum</td> </tr> </table>		Animal Model:	Male B6D2F1/J mice weighing 20–25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 μg of ovalbumin (OVA) adsorbed to 2 mg of aluminum						
Animal Model:	Male B6D2F1/J mice weighing 20–25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 μg of ovalbumin (OVA) adsorbed to 2 mg of aluminum									

	hydroxide gel in saline vehicle) <sup>[3]</sup>
Dosage:	0–10 mg/kg
Administration:	Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.)
Result:	Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463).

## REFERENCES

- [1]. Egan RW, Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. *Arzneimittelforschung*. 1999 Sep;49(9):779-90.
- [2]. Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. *Allergy Asthma Immunol Res*. 2019 Mar;11(2):291-298.
- [3]. Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. *Allergy*. 2019 Sep 4.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA